
Figure 1






Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 7C




Figure 8




Figure 9




Figure 10A






Figure 11



5' CpG NUCLEIC ACIDS AND METHODS OF USE

Figure 12



5' CpG NUCLEIC ACIDS AND METHODS OF USE

Express Mail Label No.: EV292561340US Date of Deposit: December 11, 2003 Docket No.: C1037.70038US01

Figure 13A




Figure 13B






Figure 14



Express Mail Label No.: EV292561340US


Date of Deposit: December 11, 2003 Docket No.: C1037.70038US01

Figure 15



Example: A phosphodiester linkage between the C and G of the 5' CpG dinucleotide results in enhancement of potency of immune stimulation.

Figure 16



Example: Modifications of the T preceeding the 5'-CG are allowed.